WHO's essential medicines list: Additions for migraine and cluster headache
Cephalalgia · 2026-03 · 46 (3)
DOI: 10.1177/03331024261420835 ↗Kurz gefasst
Editorial in der Zeitschrift Cephalalgia, online erschienen am 13.03.2026. Verfasst von Cristina Tassorelli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain and Behavioral Science, University of Pavia, Pavia, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
WHO’s essential medicines list (EML) is “the world’s most influential list of medicines”; more than 150 countries (threequarters of the world’s total) base their own lists upon it (1).Historically, people affected by primary headache disorder shave been poorly served by the EML. Until this year, only migraine was featured. Acute treatments were limited toacetyl salicylic acid, paracetamol (acetaminophen) and sumatriptan, with ibuprofen listed only for children. Propranolol was the sole preventative drug. The EML is reviewed biennially, and, since 2007, additions to it have been an unfulfilled ambition of the Global Campaign against Headache. Opportunity arose when, in2023, WHO invited Lifting The Burden (LTB) to submit proposals for the 2025 review. LTB asked the International Headache Society to lead the initiative and include the European Headache Federation in a joint working group(the authors). Three meetings were held to decide which drugs were to be proposed for which disorders. Tasks, which included detailed reviews of the evidence supporting each proposal, and cost-effectiveness analyses, were dele-gated to individual members. Nine proposals were submitted(Table 1), accompanied by letters of support from more than20 patient or scientific organisations (supplemental material).The overall workload was substantial (2).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Brain and Behavioral Science, University of Pavia, Pavia, Italy.
- IRCCS Mondino Foundation, Headache Science and Rehabilitation Unit, Pavia, Italy.
- Department of Neurology, Konventhospital Barmherzige Brüder, Linz, Austria.
- DREAM program, Community of Sant'Egidio, Rome, Italy.
- Global Neurology Program, International Affairs, IRCCS C. Besta Neurologic Institute, Milan, Italy.
- Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
ORCID-Profile: Cristina Tassorelli, Massimo Leone, Mario Fp Peres, Patricia Pozo-Rosich, Francesca Puledda, Simona Sacco, Derya Uludüz
Zitieren
APA
Tassorelli, C., Lampl, C., Leone, M., MaassenVanDenBrink, A., Peres, M. F., Pozo-Rosich, P., Puledda, F., Sacco, S., Tinelli, M., Uludüz, D., & Steiner, T. J. (2026). WHO's essential medicines list: Additions for migraine and cluster headache. Cephalalgia, 46(3). https://doi.org/10.1177/03331024261420835
Vancouver
Tassorelli C, Lampl C, Leone M, MaassenVanDenBrink A, Peres MF, Pozo-Rosich P, et al. WHO's essential medicines list: Additions for migraine and cluster headache. Cephalalgia. 2026;46(3). doi:10.1177/03331024261420835
BibTeX
@article{Tassorelli2026,
author = {Tassorelli, Cristina and Lampl, Christian and Leone, Massimo and MaassenVanDenBrink, Antoinette and Peres, Mario Fp and Pozo-Rosich, Patricia and Puledda, Francesca and Sacco, Simona and Tinelli, Michela and Uludüz, Derya and Steiner, Timothy J},
title = {WHO's essential medicines list: Additions for migraine and cluster headache},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {3},
doi = {10.1177/03331024261420835}
}
EUVIMED